PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/954,571
Filing Date	September 11, 2001
First Named Inventor	Kenneth R. CHIEN
Group Art Unit	~~1646~~ 1638
Examiner Name	unknown KAUSHAL

Sheet	1	of	2	Attorney Docket Number	6627-PA0123

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
SR	1	5,652,122		Frankel et al.	07-29-1997

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Foreign Patent Document Number[4] (if known)	Foreign Patent Document Kind Code[5]	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
SR	2	PCT	WO 00/25804		The Regents of the University of California	05-11-2000	
SR	3	PCT	WO 97/37224		Medical Research Council	10-09-1997	
SR	4	PCT	WO 99/30696		Orion Corporation	06/24/1999	
SR	5	France	2,753,722 (abstract translated)		Smithkline Beecham	03-27-1998	X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SR	6	Dillmann, Wolfgang, Influences of Increased Expression of the Ca^{2+} ATPase of the Sarcoplasmic Reticulum by a Transgenic Approach on Cardiac Contractility. Annals New York Academy of Sciences, pp. 43-48, 1998	
SR	7	Donahue, J. Kevin et al. Ultrarapid, highly efficient viral gene transfer to the heart. Proc.Natl.Acad.Sci. USA vol. 94, 4664-4668, 1997	

Examiner Signature		Date Considered	5/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/954,571
Filing Date	September 11, 2001
First Named Inventor	Kenneth R. CHIEN
Group Art Unit	~~1646~~
Examiner Name	~~unknown~~
Attorney Docket Number	6627-PA0123

Sheet 2 of 2

	8	He, Huaping et al. Effects of Mutant and Antisense RNA of Phospholamban on SR Ca^{2+} -ATPase Activity and Cardiac Myocyte Contractility. Circulation, 974-980, 1999	
	9	He, Huaping et al. Influence of an Antisense Phospholamban Transcribed by an Adenoviral Vector on Ca^{2+} ATPase in Cardiac Myocytes. Journal of Molecular and Cellular Cardiology, vol. 29, No. 6, A181, 1997	
	10	Ikeda, Yasuhiro et al. In Vivo Gene Transfer of Deficient δ-Sarcoglycan Protein in BIO14.6 Cardiomyopathic Hamster Hearts. Circulation, 313, 2000	
	11	Koss, Kimberly et al. Phospholamban: A Prominent Regulator of Myocardial Contractility. Circulation Research, vol. 79. No. 6, 1059-1063, 1996	
	12	Logeart, Damien et al. Highly Efficient Adenovirus-Mediated Gene Transfer to Cardiac Myocytes after Single-Pass Coronary Delivery. Human Gene Therapy 11:1015-1022, 2000	
	13	Logeart, Damien et al. How to Optimize In Vivo Gene Transfer to Cardiac Myocotes: Mechanical or Pharmacological Procedures? Human Gene Therapy 12:1601-1610, 2001	
	14	Toyofuku, Toshihiko et al. Amino Acids Glu^2 to Ile^{18} in the Cytoplasmic Domain of Phospholamban Are Essential for Functional Association with the Ca^{2+}-ATPase of Sarcoplasmic Reticulum. The Journal of Biological Chemistry, vol. 269, No. 4, 3088-3094, 1994	

Examiner Signature		Date Considered	5/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. *Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	4

Complete if Known	
Application Number	09/954,571
Filing Date	September 11, 2001
First Named Inventor	Kenneth CHIEN
Group Art Unit	~~1646~~ 1636
Examiner Name	Unknown KAOSHAL
Attorney Docket Number	6627-PA0123

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		NONE			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4] (if known)	Kind Code[5]	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
			NONE				

Examiner Signature		Date Considered	5/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]*Unique citation designation number.* [2]*See attached Kinds of U.S. Patent Documents.* [3]*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).* [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known	
Substitute for form 1449A/PTO				Application Number	09/954,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	September 11, 2001
				First Named Inventor	Kenneth CHIEN
(use as many sheets as necessary)				Group Art Unit	~~1646~~
				Examiner Name	Unknown
Sheet	2	of	4	Attorney Docket Number	6627-PA0123

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	Arber, S., et al (1997) MLP-deficient mice exhibit a diruption of cardiac cytoarchitechtural organization, dilated cardiomyopathy, and heart failure. *Cell.* **88**:393-403.	
	2	Christensen, G. et al. (2000) High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates. *Circulation.* **101**:178-84.	
	3	Coral-Vazquez, R. et al. (1999) Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. *Cell.* **98**:465-74.	
	4	French, B.A. et al. (1994) Direct *in vivo* transfer into porine myocardium using replication-deficient adenoviral vectors. *Circulation.* **90**:2414-24.	
	5	Frommes, Y. et al. (1999) Gene delivery in the myocardium by intrapericardial injection. *Gene Ther.* **6**:683-8.	
	6	Greelish, J.P. et al. (1999) Stable restoration of the sarcoglycam complex in dystrophic muscle perfused with histamine and recombinant adeno-associated viral vector.*Nat. Med.* **5**:439-43.	
	7	Gutzman, R.J. et al. (1993) Efficient gene transfer into myocardium by direct injection of adenovirus vectors. *Cric. Res.* **73**: 1202-7.	
	8	Hajjar, R.J. et al. (1998) Modulation of ventricular function through gene transfer *in vivo. Proc. Natl. Acad. Sci., USA.* **95**:5251-5256.	

Examiner Signature		Date Considered	5/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/954,571
Filing Date	September 11, 2001
First Named Inventor	Kenneth CHIEN
Group Art Unit	~~1646~~
Examiner Name	~~Unknown~~
Attorney Docket Number	6627-PA0123

Sheet	3	of	4

	9	Holt, K.M. et al. (1998) Functional rescue of the sarcoglycam complex in BIO 14.6 hamster using delta-sarcoglycan gene transfer. *Mol. Cell.* **1**:841-8	
	10	Johnson, L.G. (1992) Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. *Nat. Genet.* **2**:21-5.	
	11	Kaplitt, M.G. et al. (1996) Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. *Ann. Thorac. Surg.* **62**:1669-76.	
	12	Maeda, Y., et al. (1998) Efficient gene transfer into cardiac myocytes using adeno-associated virus (AAV) vectors. *J. Mol. Cell. Cardiol.* **30**:1341-8.	
	13	Maurice, J., et al. (1999) Enhancement of cardiac function after adenoviral-mediated *in vivo* intracoronary beta-2 adrenergic receptor gene delivery. *J. Clin. Invest.* **104**:21-9.	
	14	Miyamoto, M.I., et al. (2000) Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. *Proc. Natl. Acad. Sci. USA.* **97**:793-98.	
	15	Mohri, H. et al. (1969) Method of surface-induced deep hypothermia for open-heart surgery in infants. *J. Thorac. Cardiovasc. Surg.* **58**:262-70.	
	16	Nigro, V., et al. (1997) Identification of the Syrian hamster cardiomyopathy gene. *Hum. Mol. Genet.* **6**:601-7.	
	17	Ryoke, T., et al. (1999) Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. *Circulation.* **100**:1734-43.	
	18	Sakamoto, A., et al. (1997) Both hypertrophic and dilated cardiomyopathies are caused by mutation in the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. *Proc. Natl. Acad. Sci. USA.* **94**:13873-8.	

Examiner Signature		Date Considered	5/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

H:\Karen\6627-UCSD\PA0123\IDSSB08.02.H06.wpd

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/954,571
Filing Date	September 11, 2001
First Named Inventor	Kenneth CHIEN
Group Art Unit	~~1646~~
Examiner Name	~~Unknown~~
Attorney Docket Number	6627-PA0123

Sheet 4 of 4

SL	19	Shah, A.S. et al. (2001) In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. *Circulation* **103**:1311.	
SL	20	Svensson, E.C., et al. (1999) Efficient and stable transduction of cardiomyocytes after intramyocardial infection or intracoronary perfusion with recombinant adeno-associated virus vectors. *Circulation.* **99**:201-5.	
SL	21	Toyofuku, E., et al. (1994) Amino acids Glu2 to Ile 18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca^{2+}-ATPase of the sarcoplasmic reticulum. **269**:3088-94.	
SL	22	Xiao, X., Li, J., and Samulski, R.J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper virus. *J. Virol.* **72**:2224-32.	

Examiner Signature		Date Considered	5/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.